newscontact us

ThermoGenesis Corp. Reports Second Quarter Fiscal 2014 Results

Company Obtains Approval for Acquisition of TotipotentRX and Achieves Significant Clinical Milestones

RANCHO CORDOVA, Calif., Feb. 14, 2014 (GLOBE NEWSWIRE) — ThermoGenesis Corp. (Nasdaq:KOOL) (“ThermoGenesis”), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today reported financial results for the second quarter of fiscal 2014.

021414 FY14Q2 Earnings Call Press Release Final